Sincalide (Kinevac)
Diagnostic cholecystokinetic agent (synthetic CCK octapeptide)
Sincalide (Kinevac)
Forms and strengths
Form: TabletStrength: 5 mcg/vial (1 mcg/mL after reconstitution)
References
Indication
- Sincalide is used to stimulate gallbladder contraction during cholecystography (gallbladder imaging), allowing visualization of the gallbladder and bile ducts and collection of bile for analysis.
- Sincalide is used together with secretin (the Secretin-Kinevac test) to stimulate pancreatic secretions for analysis, such as in evaluating suspected pancreatic cancer.
- Sincalide is used to relieve postoperative ileus that is not complicated by inflammation, tumors, or other obstruction of the digestive tract.
- Sincalide is used to decrease the transit time of contrast media through the small bowel during radiologic studies.
Pregnancy
- The safety of sincalide has not been established in pregnant women.
- Because sincalide affects smooth muscle, it may theoretically trigger spontaneous abortion or premature labour in pregnant patients, so it should be used cautiously and only when clinically necessary.
Breastfeeding
- It is not known whether sincalide is excreted into human breast milk.
- Because many drugs pass into breast milk, caution should be exercised when giving sincalide to a breastfeeding patient.
Geriatrics
- Clinical studies of sincalide did not include enough patients aged 65 and older to determine whether they respond differently than younger patients.
Pediatrics
- The safety and efficacy of sincalide in children have not been established, so it is not authorized for pediatric use in Canada.
Dosage & Administration
- For gallbladder contraction during cholecystography, sincalide is given as a slow intravenous injection over 30 to 60 seconds, dosed by body weight; a second, higher dose may be given if gallbladder contraction is not satisfactory after 15 minutes.
- For the Secretin-Kinevac test of pancreatic function, sincalide is given as a slow intravenous infusion over 30 minutes, starting 30 minutes after a separate secretin infusion is begun.
- For postoperative ileus or to speed transit of contrast through the small bowel, sincalide is injected over 30 to 60 seconds; the dose may be repeated or increased at intervals if the initial response is inadequate, up to a defined maximum number of doses.
- After reconstitution with sterile water for injection, the solution may be stored under refrigeration for up to 24 hours, after which any unused portion must be discarded.
- Sincalide is intended for single-procedure administration by trained personnel and is not intended for ongoing self-administration.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Symptoms of sincalide overdose are typically mild and short-lived gastrointestinal effects, including abdominal discomfort, cramping, nausea, vomiting, and diarrhea.
- Dizziness and flushing may also occur with an excessive dose.
- Overdose symptoms are managed with symptomatic treatment and are expected to resolve over a short period.
Common side effects
- Abdominal discomfort or cramping may occur.
- Nausea may occur.
- Vomiting may occur.
- Dizziness may occur.
- Flushing may occur.
- Sweating may occur.
- An urge to defecate may occur.
- Diarrhea may occur less commonly.
- Headache may occur less commonly.
- A bitter taste in the mouth may occur less commonly.
- Shortness of breath may occur less commonly.
- Pain at the injection site may occur less commonly.
- Tremor of the limbs may occur less commonly.
- Sneezing may occur less commonly.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Anaphylaxis and other serious hypersensitivity reactions have been reported during or within an hour of sincalide administration.
- Transient reduced tone of the lower esophageal sphincter can cause acid reflux during and shortly after the procedure.
- Transient delayed gastric emptying can occur, which may affect a concurrent upper gastrointestinal imaging study.
- Stimulated gallbladder contraction could theoretically dislodge small gallstones, causing them to lodge in the cystic or common bile duct, though this risk is considered minimal at recommended doses.
- Seek urgent medical attention for wheezing, difficulty breathing, swelling of the face or throat, or signs of a severe allergic reaction during or after the injection.
Use with caution
- Use with caution in patients with suspected duodenal, gastric, or pyloric ulcers, or gastrointestinal bleeding or bowel ulceration.
- Use with caution when a concurrent upper gastrointestinal series is planned, since sincalide can transiently delay gastric emptying.
- Use with caution when a barium enema examination is also planned, since sincalide increases bowel motility and can make the examination more difficult to perform.
- Use with caution in patients with known small gallstones, given the small theoretical risk of stone migration into the bile ducts.
- Use with caution in patients with sulfite sensitivity, even though the formulation's trace sulfite content should not prevent use when the test is clinically needed; appropriate medical support for a possible reaction should be available.
- Use with caution in patients previously exposed to sincalide, since sensitization, although not reported, remains a theoretical possibility.
Contraindications
- Contraindicated in patients with known hypersensitivity to sincalide or to any non-medicinal ingredient in the formulation.
- Contraindicated in patients with known hypersensitivity to sulfites, since the product contains sodium metabisulfite.
- Contraindicated in situations where a fatty meal would be inappropriate, including acute pancreatitis, acute cholecystitis, cystic or common bile duct obstruction, gallbladder infection or empyema, small gallbladder stones, appendicitis, bowel perforation, peritonitis, a bleeding or perforating peptic ulcer, pyloric stenosis, mechanical bowel obstruction, or an acute abdomen in general.
Drug interactions
- Formal drug interaction studies have not been conducted with sincalide.
- Drugs that stimulate or inhibit gallbladder motility or contraction may interfere with the gallbladder's response to sincalide; consider whether such drugs should be held before testing.
- Medications affecting smooth muscle tone or pancreatic secretion could theoretically alter the results of sincalide-stimulated diagnostic testing, so recent relevant medication use should be reviewed before the procedure.
Food interactions
- Sincalide is given by intravenous injection in a monitored clinical or radiology setting, so the empty-stomach/with-food distinction that applies to oral medicines does not apply; however, patients are typically asked to fast before sincalide-stimulated gallbladder or pancreatic function testing, since a recent meal can itself cause gallbladder contraction and confound the results.
Time of administration
- Sincalide is administered as a single injection or infusion at the time of the diagnostic procedure, timed and dosed by the healthcare team performing the test; it is not a medicine taken on a regular home schedule.
Storage
- Store unreconstituted Kinevac vials at room temperature (15-30°C).
- After reconstitution, the solution may be refrigerated for up to 24 hours, after which any unused portion must be discarded.
Patient take-away
- Sincalide is a diagnostic agent given as an injection to help doctors visualize your gallbladder or test your pancreatic function; it is not a medicine you take regularly at home.
- Common effects such as brief stomach cramping, nausea, or flushing during or shortly after the injection are usually mild and pass quickly.
- Tell the healthcare team performing your test about any allergies, especially to sulfites, and about any digestive conditions you have.
- Seek immediate medical attention for any signs of a severe allergic reaction during or shortly after your test.